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The CD4 molecule, which is expressed by a subset of mature human T cells,
has been identified as the cellular receptor for the human immunodeficiency
virus type I (HIV I)' (1, 2). In searching for the putative region in the HIV I
envelope protein that interacts with the CD4 receptor, we postulated that this
virus had evolved to mimic the natural ligand of CD4. It was previously estab-
lished that CD4 plays an auxiliary role during T cell activation, probably by
interacting with MHC class II molecules on APCs that also serve as restriction
elements for presentation of foreign antigens to the T cell receptors (3-5).
Furthermore, results from a study in which chimeric class I/class II molecules
bearing L cells were used led us to suspect that the NH2-terminal domain ofthe
MHC class II ,B chain (,B 1 domain) is involved in CD4 binding (5).
In this report we describe a computer search comparing the conserved amino
acid regions of HLA class 11 a and 0 chains with the amino acid sequences of
HIV I proteins. This search identified an homology between two highly con-
served sequences in the 0 1 domain of HLA class II molecules and in the gp41
region of HIV I envelope protein.
To assess the biological relevance of this homology, peptides from the con-
served regions of HIV gp41 and HLA class II were synthesized and tested for
their ability to generate antibodies that would recognize the native protein
molecules. This report describes the generation of murine mAbs against the
gp41-derived peptide and their crossreactivity on native HIV I env as well as on
human class II antigens. Moreover, in screening of HIV I-infected individuals,
'Abbreviations used in this paper:
￿
AA, amino acids; CSA, chicken serum album; HIV 1, human
immunodeficiency virus type I.
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35% of AIDS patients were found to have circulating antibodies that bind to the
monomorphic class II-derived peptide . Such autoantibodies could conceivably
contribute to the immune abnormalities in AIDS patients .
Materials and Methods
Computer Search .
￿
The amino acid sequences ofhuman class 11 antigens were deduced
from the DNA sequences of cloned a and 0 genes ofDR, DQ, and DP subregions from
several alleles that were recently published (6) . For our computer search,we first identified
the most conserved regions in the extracellular domains ofhuman Class II a and ,8 chains .
These conserved regions were then compared with the published sequences of HIV I
proteins (env, gag, pol, and 3'orf) using the SFASTP program (devised by W . Pearson),
which is based on a modification of an algorithm by Wilbur and Lipman (7). A high
degree of homology was found between a conserved region located in the ft 1 domain of
DR and DQ (amino acids [AA] 19-25) and the COOH terminus of HIV I gp41 (the
transmembrane segment of the gp160 env, AA 838-844) . This region is also highly
conserved among different isolates of HIV I . This high order of sequence homology was
not equaled in the entire available protein data base (Protein Identification Resource No .
6, 1986) except for two DNA-directed polymerases .
Synthesis ofPeptides.
￿
The peptides used in this study were synthesized according to a
previously described protocol (8) . Briefly, peptides were synthesized using an automated
synthesizer (model 430A ; Applied Biosystems Inc ., Foster City, CA) . The peptides were
released from the solid-phase resin by treating the protected peptides with anhydrous
hydrofluoric acid containing 10% thioanisole or 10% anisole . The peptides were then
extracted with ethyl acetate, dissolved in 20 ml 10% acetic acid, filtered to remove the
resin, and lyophilized . Purity was verified by HPLC and amino acid analysis . The peptides
were conjugated to chicken serum albumin (CSA) as previously described (8) .
Generation ofMurine mAbs.
￿
BALB/c mice (Jackson Laboratories, Cold Spring Harbor,
ME) were immunized with 1 mg CSA peptide in CFA followed by three additional
injections in IFA at 2-wk intervals . Spleen cells from mice with high antibody titers were
fused to the NS-1 nonsecreting plasmacytoma and hybridomas were selected in HAT-
containing medium . The hybridomas secreting antipeptide antibody were cloned by
limiting dilution (0 .3 cells/well).
Antibody Assays.
￿
ELISAs were performed by coating plates (Immunolon I ; Dynatech
Laboratories, Inc ., Alexandria, VA) with peptides at 10 Pg/ml in bicarbonate buffer at
pH 9 .6 . BSA, 1 mg/ml in PBS, was added to block unbound sites . Mouse monoclonal
IgM antibodies or patients' sera were incubated at various dilutions for 2 h at room
temperature . This was followed by incubation with either goat anti-mouse R chain-
specific or goat anti-human y chain-specific alkaline phosphatase-linked antibody (Sigma
Chemical Co ., St. Louis, MO) for 2 h at room temperature . Between each step extensive
washing was performed with PBS containing 0 . I% Tween 20 . Color was developed by
addition of the substrate, p-nitrophenyl phosphate (Sigma Chemical Co .) for 1-3 h at
room temperature . The optical densities were read at 405 nm using a Multiscan MC
(Titertek, Helsinki, Finland) . In the inhibition experiments, the mouse mAb against the
gp41 peptide was preincubated with CSA-peptide or CSA overnight at 4°C and then
added to the peptide-coated or HIV I-coated (Genetic Systems, Seattle, WA) plates .
FACS Analysis.
￿
Human EBV-transformed B cell lines (9) or mouse L cells transfected
with the structural genes of HLA class II antigens DR, DQ, and DP (Sekaly, R ., and E .
Long [10]) were stained with the following reagents : (a) class II-specific mAb that
recognizes monomorphic determinant present on all HLA class II antigens (Becton
Dickinson& Co., Mountain View, CA) ; (b) the newly generated murine mAb against HIV
I gp41 peptide (see above) ; or (c) a control TNP-specific murine mAb . All cells were
incubated with the mAb at 4'C for 30 min in the presence of 0.1% sodium azide . The
developing reagent, FITC goat anti-mouse Ig (H and L chain) antiserum (Cappel
Laboratories ; CooperBiomedical, Inc ., Malvern, PA) was added for 30 min at 4°C, and
the samples were analyzed in a FACS (model II ; Becton Dickinson & Co .) . Data are
presented on a logarithmic scale .916 SHARED SEQUENCE BETWEEN HIV I AND HLA CLASS II MOLECULES
FIGURE 1 . HLA class 11 and HIV I gp41 contain re-
Peptide I : HLA Class II Derived-
￿
gions with high homology to each other . Peptide I rep-
resents AA 19-25 in the 0 1 domain ofHLA class 110
Peptide II : HIV GP 41 Derivedb
￿
"E-G-T-D-R-V-I"
￿
chin . Peptide 11 represents AA 837-844 in the gp160
envelope protein of HIV I . Two dots indicates amino
IN = asn ; G = gly ; T = thr ; E = glu ; R = arg;
￿
acids that are identical in the two peptides. One dot
V = Val ; D = asp ; I = Ilea)
￿
indicates a conservative change of glutamic to aspartic
acid .
Screening ofAIDS Sera .
￿
All the patients' sera used in the study were obtained from
AIDS patients with active disease . All sera reacted with multiple HIV I proteins on
Western blots (Biotech Research Labs Inc., Rockville, MP) . The control group consisted
of normal volunteers (lab personnel) as well as five seronegative homosexuals (high risk
group) .
Results and Discussion
HLA Class II andHIV Igp41 Share a Region ofHigh Homology.
￿
Many viruses
gain access into the cytoplasm ofnew host cells by direct fusion with the plasma
membrane (11), while other viruses, such as EBV (12) and HIV I (2), use special
cellular receptors that are found on a more restricted number of cell types. The
normal function of these receptors usually involves their interaction with biolog-
ical ligands that could either be soluble compounds (12) or cell-bound molecules
expressed on the same or other cell types (3-5). It was intriguing to test the
possibility that during evolution, the latter type of viruses had developed attach-
ment sites that mimic the natural ligands of their cellular receptor . In the case
of HIV I, it was assumed that the primary sequence of these attachment sites
might bear homology to one of the natural ligands for CD4, namely, MHC class
II molecules, as was previously suggested (3-5) . Ourcomputer search, therefore,
compared 12 conserved regions in a and ,B chains ofhuman class II molecules to
HIV I proteins from 13 different isolates (see Materials and Methods) . This
analysis revealed homology between a region in the (3 1 domain ofHLADR and
DQ and the gp41 part of HIV I envelope glycoprotein . The homologous
sequences are shown in Fig . 1 . As can be seen, they share a core of five amino
acids that are identical except for a single conservative change of glutamic to
aspartic acid, which does not change the overall charge of these two regions .
To assess the functional importance of the homologous regions found in HIV
I gp41 (peptide II) and class II antigens (peptide I), the septamers were synthe-
sized, coupled to CSA, and used to immunize BALB/c mice . The spleen cells of
mice with high serum antibodies against the gp41-derived peptide were used for
the generation of hybridomas . Five hybridomas were identified that bound
strongly to the gp41-derived peptide in an ELISA. All were found to be of the
IgM isotype and K light chain.
Specificity ofAnti-gp41 mAbs .
￿
The specificity of the mAbs that were generated
from mice immunized with the gp41 peptide conjugates was examined using
ELISA plates coated with either the gp41-or HLA class II-derived peptides . As
depicted in Fig . 2, the mAbs were found to bind equally well to plates coated
with either peptide (Fig . 2A), and this binding could be blocked by CSA-gp41
peptide but not by CSA alone (Fig . 2C) . In contrast, a control mAb of the same
isotype but of different specificity (anti-TNP) did not bind to either peptide (Fig .
2A). The gp41 peptide-specific mAb also bound to plates that are coated withGOLDING ET AL.
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FIGURE 2 .
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inactivated HIV I virus from HIV I-infected CEM cells, which do not express
MHC class II . This binding could also be blocked by CSA-gp41 peptide (Fig. 2,
B and D) . No reactivity was seen on control plates coated with CSA or irrelevant
peptides . In addition, these mAb also react with the gp160 band on HIV I
immunoblots (not shown) . Thus, the mAb against the gp41-derived peptide can
recognize this sequence both in a peptide form (peptides I and II) and in the
context of the entire envelope protein .
Anti-gp41 Peptide mAbs React with Native Class H Antigens .
￿
It was of interest
to determine whether the mAb that we raised against the HIV I septamer would
also recognize native MHC class II molecules . For this purpose a panel ofEBV-
transformed B cell lines were stained in parallel with one of the following: (a) a
monomorphic anti-class II antibody (Becton Dickinson & Co .) ; (b) the gp41
peptide-specific mAb ; or (c) control anti-TNP mAbs. As can be seen in Fig . 3,
the human B cell lines were not only stained with the class II-specific mAbs (Fig .
3A), but also with the gp41 peptide-specific mAbs (Fig . 3, CandD) . In contrast,
no staining of the B cells was obtained with control TNP-specific mAbs . A panel
of class II- human cell lines, including CEM (T cell) and a fibroblast line, were
not stained by either mAb (not shown) .
To confirm that the mAbs against gp41 peptide did indeed bind to native
MHC class 11 molecules on the surface of B cells, we tested their ability to stain
murine fibroblast L cells that were transfected with the structural genes of
human DR a and (3 chains (kindly provided to us by Sekaly and Long [10]) . As
depicted in Fig . 4, the DR4-transfected L cells stained brightly with the DR-918 SHARED SEQUENCE BETWEEN HIV I AND HLA CLASS II MOLECULES
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FIGURE 3 .
￿
MarinemAb spe-
cific for HIV I gp41 peptide
bind to human EBV-trans-
formedB cell lines. TheB cell
line (1:13; reference 9) was
stained with anti-DRmAb (A),
anti-TNP mAb (B), or anti-
gp41 peptide mAb No. 4 (C)
and No . 5 (D), followed by
FITC goat anti-mouse mAb
(-). Control cells were
stained withthedeveloping re-
agent alone (- - -) .
FIGURE 4 .
￿
MurinemAb spe-
cific for HIV I gp41 peptide
binds to L cells transfected
with human DR genes. L cells
transfected with DR4 aand fl
structural genes (A-C) or with
the herpes simplex thymidine
kinase (tk) gene (D-F) were
stained with anti-DR mAb (A
and D), anti-gp41 mAb No . 4
(B and E), or anti-TNP mAb
(C andF) .
specific reagent (Becton Dickinson & Co .) (Fig . 4A), demonstrating that the
transfected a and a gene products were coexpressed on the surface of these
marine L cells that normally do not express any MHC class II antigens (Fig . 4D) .
More importantly, these DR-expressing L cells also stained positively (albeit to a
lesser degree) with the gp41 peptide-specific mAbs (Fig . 4 B) . The control L(tk*)
cell line was only transfected with a selection marker (Herpes Simplex tk gene),
and thus expresses only mouseMHC class I but not class II antigens . It was not
stained by any ofour gp41 peptide-specific mAbs (Fig . 4E) . Similar results were
obtained with murine L cells that were transfected with other class II structural
genes namely, DP andDQ (not shown) .
These data demonstrate that the mAbs raised against a conserved region in
the COOH terminus of HIV I envelope protein crossreacts with native class II
molecules that express the homologous region . Therefore, although the class II
a and ,B chains possess two extracellular domains that interact with each other
noncovalently to form a complex tertiary structure, mAb against a 6 chain0 .9
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FIGURE 5.
￿
Reactivity of AIDS sera against human HLA class
11-derived peptide I . Sera from 43 AIDS patients and 23
controls (18 seronegative normal volunteers and 5healthy male
homosexuals) were tested by ELISA for reactivity to the HLA
class 11-derived peptide I (shown in Fig . 1). The broken line
represents the mean absorbance value (405 nm) of the control
group .
peptide could recognize the native molecules . This was of interest since most
antibodies against short peptides derived from class II molecules do not react
with the native two-chain structure . The reactivity found with our mAb indicates
that the conserved region, which maps to the NH2 terminus of the class II ,B
chain, is not buried inside the native class II molecules and is therefore accessible
for recognition by the murine mAb .
Screening of AIDS Patients for Anti-class II Peptide Reactivity .
￿
The findings
described above led us to consider the possibility that HIV I-infected individuals
may generate antibodies against the gp41 COON-terminal region which could
crossreact with self class II antigens and thus behave as autoantibodies . To test
this possibility, we screened sera from 45 seropositive AIDS patients as well as
23 controls. The AIDS patients' sera all tested positive against HIV I and
contained antibodies against different viral products including gp41 as detected
on immunoblots . The control group consisted of either normal volunteers (n =
18) or healthy seronegative homosexuals (5 high risk controls) . The sera were
tested for binding to ELISA plates coated with the HLA class II-derived peptide .
As can be seen in Fig. 5, 15 sera from the seropositive patient group (36%)
contained antibodies that reacted with the class 11-derived peptide with absorb-
ance (405 nm) >3 SD above the mean control value . Two of the control sera
were also positive, but interestingly, they were obtained from seronegative
homosexuals (high risk individuals) . It is possible, therefore, that the reactivity
found against a class 11-derived peptide, which bears a high degree ofhomology
to a region in the gp41 protein, resulted from exposure of these individuals to
HIV I that was not yet detectable by standard HIV I serological assays .
AIDS Patients' Antibodies That Bind to Peptide I Crossreact on Whole Class II
Molecules. It was important to determine whether the reactivity against the class
11-derived peptide found in the AIDS patients' sera was specifically against this
region of the class 11 molecules (AA 19-25), and more importantly, whether the920 SHARED SEQUENCE BETWEEN HIV I AND HLA CLASS II MOLECULES
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FIGURE 6 . AIDS sera that bind to class 11-derived peptide I bind also to intact class II
molecules. Sera from five AIDS patients (+), two seronegative individuals (-), and DR4-
specific alloantiserum were diluted 1 :50 and tested for binding to ELISA plates coated with
(A) the class 11-derived peptide I (/4 1 domain, AA 19-25) ; (B) class II-rich cell extract from
the H9 (DR4,DQ3) humanT cell line; (C) class II-negative cell extract from the CEM cell
line ; (D) a control, conserved class II-derived peptide (,9 1 domain, AA 38-45); and (E) a
control peptide derived from tetanus toxoid. All plates were coated with the indicated
preparations at 10 Ag/ml protein concentration .
same antibodies crossreact on intact class II molecules (as was the case with the
murine antipeptide mAb) .
Five of the AIDS sera that reacted with the class 11-derived peptide I were
tested in parallel for reactivity against (a) class 11-derived peptide I ; (b) human
class II-enriched cell extract preparation from uninfected H9 (DR4,DQ3) cells
(prepared by Dr . M . Phelan, Division of Virology, FDA ; this extract contains
intact class II heterodimers that are recognized on Western blots by DR4-specific
human alloantiserum and by murine mAb against human class 11 monomorphic
determinant, but not by alloantisera specific for DR2, 3, 5, and 7) ; (c) identically
prepared extract from the class II negative cell line CEM ; (d) a control, highly
conserved, class 11-derived peptide (AA 39-45 in 0 1 domain) ; and (e) control
peptide derived from Tetanus toxoid, not related to either HIV I or to class II
molecules . The data depicted in Fig . 6 clearly show that the patients' sera, which
reacted with the class 11-derived peptide I, also bound to plates coated with the
intact class II molecule-containing extracts, but not with similar extracts obtained
from the class 11- cell line . Furthermore, no reactivity was seen with control
peptides derived from another class 11 0 1 domain conserved region (AA 39-45)
or from tetanus toxoid . The seronegative control sera (from uninfected individ-
uals) did not react with either the class 11-derived peptide I or with the class II-
enriched extract, but did bind somewhat to the tetanus toxoid-derived peptideW c
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FIGURE 7 .
￿
Correlation of AIDS sera-binding
to class II-derived peptide I and to class II-rich
cell extract . Linear regression analysis wasused
to establish the correlation between binding to
class II-derived peptide I (y axis) and binding
to intact class II molecules from H9 cell extract
(x axis) for 35 AIDS patients. Thebroken lines
represent themean+ 2 SD values ofthe control
sera tested in parallel for binding to the same
ELISA plates.
FIGURE 8. Soluble CSA peptide I blocks
binding of AIDS sera to class II-derived pep-
tide I and to class II-rich cell extract . Patient
sera (1:50 dilutions) were preincubated with
CSA(/) or CSA peptide I (®) (4 mg/ml) over-
night at 4°C and were then added to ELISA
plates coated with class II-rich cell extract
(DR4, DQ3) (upper panel) or class II-derived
peptide I (lower panel). The data is expressed
as percent inhibition of absorbance (405 nM)
compared to the binding of sera preincubated
with PBS .
(probably reflecting their immune memory against tetanus toxoid, which is a
commonly used vaccine) . Thehuman anti-DR4 alloantiserum was also tested . As
expected, it reacted with the DR4-containing extractbut not with the la- extract,
or with the nonpolymorphic class II-derived peptides .
Three of the patients whose sera were tested in this experiment were HLA
typed and were found to express at least one of the class 11 antigens that are
present in the class II-rich extract. Patients 302 and 311 areDQ3+, and patient
306 is DR4 . Thus, it seems that irrespective of their HLA haplotype, AIDS
patients may produce antibodies that recognize a nonpolymorphic region on
their class II molecules . A similar screen was performed on sera from 38 patients,
and a good correlation (r= 0.8260) was found between their reactivity with the
class II-derived peptide I and with the class II heterodimer-containing extract
(Fig. 7) .
To further establish the specificity of the binding observed in the ELISAs
(Figs. 5-7), patients' sera were preincubated with soluble CSA peptide I or with
CSA, and then added to the ELISA plates . As can be seen in Fig. 8, soluble CSA922 SHARED SEQUENCE BETWEEN HIV I AND HLA CLASS II MOLECULES
peptide I could efficiently block binding of AIDS sera not only to the peptide I-
coated plates (lower panel), but also to the intact class 11 molecules (upper panel).
Our study suggests that about a third of AIDS patients contain circulating
antibodies that react with a nonpolymorphic region of class II molecules. This
ratio, as well as the level of anti-class II antibodies detected, is probably under-
estimated because such anti-self antibodies are most likely bound to class II-
bearing cells such as B cells, macrophages, and some T cells in vivo, and are
therefore not available for detection in the ELISAs. This possibility can be tested
by examination of lymphoid cells from AIDS patients for the presence of
cytophilic antibodies specific for the gp41/class II homologous regions described
in our study.
The fact that infection with HIV I may lead to the generation ofcrossreactive
antibodies against nonpolymorphic region of self class 11 molecules in infected
individuals could be of major consequence. Such antibodies may interfere with
the normal cellularinteractions between CD4+ T cells and MHC class II-bearing
APCs. Alternatively, they could be involved in cytopathic mechanisms; e.g.,
ADCC or complement-mediated killing of class 11-expressing cells such as B
cells, macrophages, and even activated CD4' T cells. These possibilities are
currentlybeing examined in our laboratory and preliminary results demonstrate
the ability of the mAb to block proliferative responses of human CD4-bearing
cell lines. Our findings could also have important implications for HIV I vaccine
development. One of the potential vaccines currently being tested contains the
entire gp160 envelope protein that has been cloned into a Vaccinia vector. This
preparation thus contains in its COOH terminal the sequence described in this
study, and may inadvertently lead to the generation of class 11-reacting auto-
antibodies in vaccinated individuals. To avoid this outcome, it wouldbe advisable
to remove this region from the gp160 or to replace it with an inert sequence.
Summary
Homologous regions of five amino acids each, were identified in the NH2-
terminal domain of human class II ,# chains and the COOH terminus of HIV I
envelope protein. The homologous regions are highly conserved amongdifferent
DR and DQ alleles and also amongdifferent isolates ofHIV. Septamers contain-
ing these sequences were synthesized and used for the generation of murine
mAbs. The mAbs selected for this study were raised against the HIV I-derived
peptideandreacted strongly not only with the immunizing peptide, but also with
the homologous class II-derived peptide. These mAbs also reacted with native
MHC class II antigens expressed on human B cell lines and on murine fibroblast
L cell lines transfected with the genes coding for the a and # chains of human
class II antigens. Furthermore, sera from 36% ofAIDS patients tested contained
antibodies that reacted with the class II-derived peptide, as well as with intact
class II molecule-rich cell extracts. Such antibodies in HIV I-infected individuals
may recognize self class 11 antigens, triggering autoimmune mechanisms that
could contribute to the development of immunodeficiency in AIDS patients.GOLDING ET AL .
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